Brief: BrainsWay Gets FDA Clearance for Accelerated Deep TMS Protocol to Treat Major Depressive Disorder (MDD)
16/09/2025 14:13
Sept 16 (Reuters) - Brainsway Ltd BWAY.TA: BRAINSWAY RECEIVES FDA CLEARANCE FOR ACCELERATED DEEP TMS PROTOCOL FOR NON-INVASIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Source text: ID:nGNXVQbQ9 Further company coverage: BWAY.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)